Chronic Granulomatous Disease clinical trials at UCSF
2 research studies open to eligible people
EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
open to eligible males ages 3 months and up
The goal of this clinical trial is to evaluate the safety and potential efficacy of the EN-374 treatment regimen and identify a dose level for further evaluation in participants with x-linked chronic granulomatous disease. The main questions it aims to answer are: - safety of the EN-374 treatment regimen - effect of the EN-374 treatment regimen on the production of functional neutrophils with NADPH oxidase activity
San Francisco, California and other locations
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
open to all eligible people
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
San Francisco, California and other locations
Our lead scientists for Chronic Granulomatous Disease research studies include Morna Dorsey, MD, MS.
Last updated: